BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Villanueva C, Aracil C, Colomo A, Hernández-Gea V, López-Balaguer JM, Alvarez-Urturi C, Torras X, Balanzó J, Guarner C. Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding. Gastroenterology. 2009;137:119-128. [PMID: 19344721 DOI: 10.1053/j.gastro.2009.03.048] [Cited by in Crossref: 140] [Cited by in F6Publishing: 108] [Article Influence: 10.8] [Reference Citation Analysis]
Number Citing Articles
1 Hofer BS, Simbrunner B, Bauer DJM, Paternostro R, Schwabl P, Scheiner B, Semmler G, Hartl L, Jachs M, Datterl B, Staettermayer AF, Trauner M, Mandorfer M, Reiberger T. Acute hemodynamic response to propranolol predicts bleeding and nonbleeding decompensation in patients with cirrhosis. Hepatol Commun 2022. [PMID: 35808889 DOI: 10.1002/hep4.2021] [Reference Citation Analysis]
2 Chauhan A, Bhatia A. Letter: non-selective beta-blockers in cirrhosis-effect beyond portal hypertension. Aliment Pharmacol Ther 2022;56:184-5. [PMID: 35689323 DOI: 10.1111/apt.16941] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Llop E, Perelló C, Fontanilla T, de la Revilla J, Conde MH, López M, Minaya J, Ferre C, Abad J, Carrillo CF, Martínez JL, Puga NF, Trapero M, Hajra IE, Santos E, Calleja JL. Spleen Transient Elastography and Damping Index Identify a Subgroup of Patients Without an Acute or Chronic Response to Beta-Blockers. Front Med 2022;9:900073. [DOI: 10.3389/fmed.2022.900073] [Reference Citation Analysis]
4 Kristensen H, Kimer N, Møller S. Indications and methods for measuring portal hypertension in cirrhosis. Scand J Gastroenterol 2022;:1-9. [PMID: 35514215 DOI: 10.1080/00365521.2022.2065889] [Reference Citation Analysis]
5 Rabiee A, Garcia‐tsao G, Tapper EB. Nonselective Beta‐Blockers in Portal Hypertension: Why, When, and How? Clinical Liver Disease. [DOI: 10.1002/cld.1182] [Reference Citation Analysis]
6 Kreisel W, Lazaro A, Trebicka J, Grosse Perdekamp M, Schmitt-Graeff A, Deibert P. Cyclic GMP in Liver Cirrhosis-Role in Pathophysiology of Portal Hypertension and Therapeutic Implications. Int J Mol Sci 2021;22:10372. [PMID: 34638713 DOI: 10.3390/ijms221910372] [Reference Citation Analysis]
7 Yao Q, Chen W, Yan C, Yu J, Jiang T, Cao H. Efficacy and Safety of Treatments for Patients With Portal Hypertension and Cirrhosis: A Systematic Review and Bayesian Network Meta-Analysis. Front Med (Lausanne) 2021;8:712918. [PMID: 34540867 DOI: 10.3389/fmed.2021.712918] [Reference Citation Analysis]
8 He L, Lou L. Letter: the need to reconsider the liver-specific benefit of carvedilol. Aliment Pharmacol Ther 2021;54:348. [PMID: 34236095 DOI: 10.1111/apt.16383] [Reference Citation Analysis]
9 Italian Association for the Study of the Liver (AISF). Portal Hypertension and Ascites: Patient-and Population-centered Clinical Practice Guidelines by the Italian Association for the Study of the Liver (AISF). Dig Liver Dis 2021;53:1089-104. [PMID: 34321192 DOI: 10.1016/j.dld.2021.06.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Thabut D, Weil D, Bouzbib C, Rudler M, Cassinotto C, Castéra L, Serste T, Oberti F, Ganne-Carrié N, de Lédinghen V, Bourlière M, Bureau C. NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF PORTAL HYPERTENSION. Clin Res Hepatol Gastroenterol 2021;:101767. [PMID: 34332128 DOI: 10.1016/j.clinre.2021.101767] [Reference Citation Analysis]
11 Sharma S, Agarwal S, Gunjan D, Kaushal K, Anand A, Gopi S, Mohta S, Saraya A. Outcomes of Portal Pressure-Guided Therapy in Decompensated Cirrhosis With Index Variceal Bleed in Asian Cohort. J Clin Exp Hepatol 2021;11:443-52. [PMID: 34276151 DOI: 10.1016/j.jceh.2020.11.001] [Reference Citation Analysis]
12 Garcia-Pagan JC, Francoz C, Montagnese S, Senzolo M, Mookerjee RP. Management of the major complications of cirrhosis: Beyond guidelines. J Hepatol 2021;75 Suppl 1:S135-46. [PMID: 34039484 DOI: 10.1016/j.jhep.2021.01.027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
13 Rittig N, Aagaard NK, Villadsen GE, Sandahl TD, Jessen N, Grønbaek H, George J. Randomised clinical study: acute effects of metformin versus placebo on portal pressure in patients with cirrhosis and portal hypertension. Aliment Pharmacol Ther 2021;54:320-8. [PMID: 34165199 DOI: 10.1111/apt.16460] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
14 Danielsen KV, Hove JD, Nabilou P, Yin M, Chen J, Zhao M, Kallemose T, Teisner AS, Siebner HR, Ehman RL, Møller S, Bendtsen F. Using MR elastography to assess portal hypertension and response to beta-blockers in patients with cirrhosis. Liver Int 2021;41:2149-58. [PMID: 34060714 DOI: 10.1111/liv.14981] [Reference Citation Analysis]
15 Petrisor A, Stanescu AMA, Papacocea IR, Panaitescu E, Peagu R, Moldoveanu AC, Fierbinteanu-Braticevici C. Non-invasive laboratory, imaging and elastography markers in predicting varices with high risk of bleeding in cirrhotic patients. Rom J Intern Med 2021;59:194-200. [PMID: 33544557 DOI: 10.2478/rjim-2021-0001] [Reference Citation Analysis]
16 Agarwal S, Sharma S, Kumar M, Venishetty S, Bhardwaj A, Kaushal K, Gopi S, Mohta S, Gunjan D, Saraya A, Sarin SK. Development of a machine learning model to predict bleed in esophageal varices in compensated advanced chronic liver disease: A proof of concept. J Gastroenterol Hepatol 2021. [PMID: 34050561 DOI: 10.1111/jgh.15560] [Reference Citation Analysis]
17 Ferrusquía-acosta J, Bassegoda O, Turco L, Reverter E, Pellone M, Bianchini M, Pérez-campuzano V, Ripoll E, García-criado Á, Graupera I, García-pagán JC, Schepis F, Senzolo M, Hernández-gea V. Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis. Journal of Hepatology 2021;74:811-8. [DOI: 10.1016/j.jhep.2020.10.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
18 Veldhuijzen van Zanten D, Buganza E, Abraldes JG. The Role of Hepatic Venous Pressure Gradient in the Management of Cirrhosis. Clin Liver Dis 2021;25:327-43. [PMID: 33838853 DOI: 10.1016/j.cld.2021.01.002] [Reference Citation Analysis]
19 Ferstl P, Trebicka J. Acute Decompensation and Acute-on-Chronic Liver Failure. Clin Liver Dis 2021;25:419-30. [PMID: 33838858 DOI: 10.1016/j.cld.2021.01.009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Jachs M, Reiberger T. Prevention of Variceal Bleeding and Rebleeding by Nonselective Beta-Blockers: A Tailored Approach. Clin Liver Dis 2021;25:311-26. [PMID: 33838852 DOI: 10.1016/j.cld.2021.01.004] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Garcia Garcia de Paredes A, Manicardi N, Tellez L, Ibañez L, Royo F, Bermejo J, Blanco C, Fondevila C, Fernandez Lanza V, Garcia-Bermejo L, Falcon-Perez JM, Bañares R, Gracia-Sancho J, Albillos A. Molecular Profiling of Decompensated Cirrhosis by a Novel MicroRNA Signature. Hepatol Commun 2021;5:309-22. [PMID: 33553977 DOI: 10.1002/hep4.1642] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 La Mura V, Villanueva C, Abraldes JG, Bosch J. Reply. Hepatology 2020;72:1494-5. [PMID: 32246502 DOI: 10.1002/hep.31253] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Solà E, Pose E, Campion D, Piano S, Roux O, Simon-Talero M, Uschner F, de Wit K, Zaccherini G, Alessandria C, Beuers U, Caraceni P, Francoz C, Mookerjee RP, Trebicka J, Vargas V, Serra M, Torres F, Montagnese S, Krag A, Hernaez R, Korenjak M, Watson H, Abraldes JG, Kamath PS, Ginès P; LiverHope Consortium Investigators. Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium. J Hepatol 2021;74:200-19. [PMID: 32896580 DOI: 10.1016/j.jhep.2020.08.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
24 Ishikawa T, Hamamoto K, Sasaki R, Nishimura T, Matsuda T, Iwamoto T, Takami T, Sakaida I. Significant improvement in portal‐systemic liver failure symptoms and successful management of portal‐splenic venous hemodynamics by the combination of interventional radiology and pharmacotherapy. Hepatol Res 2020;50:1201-8. [DOI: 10.1111/hepr.13545] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
25 Jindal A, Bhardwaj A, Kumar G, Sarin SK. Clinical Decompensation and Outcomes in Patients With Compensated Cirrhosis and a Hepatic Venous Pressure Gradient ≥20 mm Hg. Am J Gastroenterol 2020;115:1624-33. [PMID: 32453061 DOI: 10.14309/ajg.0000000000000653] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
26 Alvarado-Tapias E, Ardevol A, Garcia-Guix M, Montañés R, Pavel O, Cuyas B, Graupera I, Brujats A, Vilades D, Colomo A, Poca M, Torras X, Guarner C, Concepción M, Aracil C, Torres F, Villanueva C. Short-term hemodynamic effects of β-blockers influence survival of patients with decompensated cirrhosis. J Hepatol 2020;73:829-41. [PMID: 32298768 DOI: 10.1016/j.jhep.2020.03.048] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
27 Møller S, Kimer N, Barløse M, Bendtsen F. Pathophysiological-based treatments of complications of cirrhosis. Scand J Gastroenterol 2020;55:383-94. [PMID: 32233873 DOI: 10.1080/00365521.2020.1744709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Gifford FJ, Dunne PDJ, Weir G, Ireland H, Graham C, Tuck S, Hayes PC, Fallowfield JA. A phase 2 randomised controlled trial of serelaxin to lower portal pressure in cirrhosis (STOPP). Trials 2020;21:260. [PMID: 32164767 DOI: 10.1186/s13063-020-4203-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
29 Rodrigues SG, Mendoza YP, Bosch J. Beta-blockers in cirrhosis: Evidence-based indications and limitations. JHEP Rep 2020;2:100063. [PMID: 32039404 DOI: 10.1016/j.jhepr.2019.12.001] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 19.5] [Reference Citation Analysis]
30 Turco L, Villanueva C, La Mura V, García-pagán JC, Reiberger T, Genescà J, Groszmann RJ, Sharma BC, Merkel C, Bureau C, Alvarado E, Abraldes JG, Albillos A, Bañares R, Peck-radosavljevic M, Augustin S, Sarin SK, Bosch J, García-tsao G. Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis. Clinical Gastroenterology and Hepatology 2020;18:313-327.e6. [DOI: 10.1016/j.cgh.2019.05.050] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 17.0] [Reference Citation Analysis]
31 Liu C, Liu Y, Shao R, Wang S, Wang G, Wang L, Zhang M, Hou J, Zhang C, Qi X. The predictive value of baseline hepatic venous pressure gradient for variceal rebleeding in cirrhotic patients receiving secondary prevention. Ann Transl Med 2020;8:91. [PMID: 32175384 DOI: 10.21037/atm.2019.12.143] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
32 Magaz M, Baiges A, Hernández-Gea V. Precision medicine in variceal bleeding: Are we there yet? J Hepatol. 2020;72:774-784. [PMID: 31981725 DOI: 10.1016/j.jhep.2020.01.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
33 Lichtenegger P, Schiefer J, Graf A, Berlakovich G, Faybik P, Baron DM, Baron-Stefaniak J. The association of pre-operative anaemia with survival after orthotopic liver transplantation. Anaesthesia 2020;75:472-8. [PMID: 31701527 DOI: 10.1111/anae.14918] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
34 Dwinata M, Putera DD, Adda’i MF, Hidayat PN, Hasan I. Carvedilol vs endoscopic variceal ligation for primary and secondary prevention of variceal bleeding: Systematic review and meta-analysis. World J Hepatol 2019; 11(5): 464-476 [PMID: 31183006 DOI: 10.4254/wjh.v11.i5.464] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 3.7] [Reference Citation Analysis]
35 Mandorfer M, Hernández-gea V, Reiberger T, García-pagán JC. Hepatic Venous Pressure Gradient Response in Non-Selective Beta-Blocker Treatment—Is It Worth Measuring? Curr Hepatology Rep 2019;18:174-86. [DOI: 10.1007/s11901-019-00469-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
36 Delgado MG, Bosch J. HVPG Measurements as a Surrogate of Clinical Events in Cirrhosis: Experience from Clinical Trials. Curr Hepatology Rep 2019;18:164-73. [DOI: 10.1007/s11901-019-00461-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Abraldes JG, Trebicka J, Chalasani N, D'Amico G, Rockey DC, Shah VH, Bosch J, Garcia-Tsao G. Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension. Hepatology 2019;69:1287-99. [PMID: 30318607 DOI: 10.1002/hep.30314] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 9.3] [Reference Citation Analysis]
38 Kim BH, Chung JW, Lee CS, Jang ES, Jeong SH, Kim N, Kim JW. Liver volume index predicts the risk of esophageal variceal hemorrhage in cirrhotic patients on propranolol prophylaxis. Korean J Intern Med 2019;34:1233-43. [PMID: 30759966 DOI: 10.3904/kjim.2018.120] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Reverter E, Lozano JJ, Alonso C, Berzigotti A, Seijo S, Turon F, Baiges A, Martínez‐chantar ML, Mato JM, Martínez‐arranz I, La Mura V, Hernández‐gea V, Bosch J, García‐pagán JC. Metabolomics discloses potential biomarkers to predict the acute HVPG response to propranolol in patients with cirrhosis. Liver Int 2019;39:705-13. [DOI: 10.1111/liv.14042] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
40 Barr RG. Ultrasound of Diffuse Liver Disease Including Elastography. Radiol Clin North Am 2019;57:549-62. [PMID: 30928077 DOI: 10.1016/j.rcl.2019.01.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
41 Garcia-Tsao G, Fuchs M, Shiffman M, Borg BB, Pyrsopoulos N, Shetty K, Gallegos-Orozco JF, Reddy KR, Feyssa E, Chan JL, Yamashita M, Robinson JM, Spada AP, Hagerty DT, Bosch J. Emricasan (IDN-6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension. Hepatology 2019;69:717-28. [PMID: 30063802 DOI: 10.1002/hep.30199] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 15.0] [Reference Citation Analysis]
42 Piyachaturawat P, Siramolpiwat S, Sonsiri K, Tangkijvanich P, Treeprasertsuk S. Changes in transient elastography in early cirrhotic patients after receiving nonselective B-blocker for primary variceal bleeding prophylaxis: Three-month follow up. JGH Open 2018;2:172-7. [PMID: 30483585 DOI: 10.1002/jgh3.12063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
43 Reiberger T, Bucsics T, Paternostro R, Pfisterer N, Riedl F, Mandorfer M. Small Esophageal Varices in Patients with Cirrhosis-Should We Treat Them? Curr Hepatol Rep. 2018;17:301-315. [PMID: 30546995 DOI: 10.1007/s11901-018-0420-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
44 Fortea JI, Puente Á, Ruiz P, Ezcurra I, Vaquero J, Cuadrado A, Arias-Loste MT, Cabezas J, Llerena S, Iruzubieta P, Rodríguez-Lope C, Huelin P, Casafont F, Fábrega E, Crespo J. Impact of an acute hemodynamic response-guided protocol for primary prophylaxis of variceal bleeding. World J Clin Cases 2018; 6(13): 611-623 [PMID: 30430116 DOI: 10.12998/wjcc.v6.i13.611] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
45 Karagiannakis DS, Voulgaris T, Siakavellas SI, Papatheodoridis GV, Vlachogiannakos J. Evaluation of portal hypertension in the cirrhotic patient: hepatic vein pressure gradient and beyond. Scand J Gastroenterol 2018;53:1153-64. [PMID: 30345856 DOI: 10.1080/00365521.2018.1506046] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
46 Deibert P, Lazaro A, Stankovic Z, Schaffner D, Rössle M, Kreisel W. Beneficial long term effect of a phosphodiesterase-5-inhibitor in cirrhotic portal hypertension: A case report with 8 years follow-up. World J Gastroenterol 2018; 24(3): 438-444 [PMID: 29391766 DOI: 10.3748/wjg.v24.i3.438] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
47 Baiges A, Hernández-Gea V, Bosch J. Pharmacologic prevention of variceal bleeding and rebleeding. Hepatol Int 2018;12:68-80. [PMID: 29210030 DOI: 10.1007/s12072-017-9833-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
48 Reiberger T, Püspök A, Schoder M, Baumann-Durchschein F, Bucsics T, Datz C, Dolak W, Ferlitsch A, Finkenstedt A, Graziadei I, Hametner S, Karnel F, Krones E, Maieron A, Mandorfer M, Peck-Radosavljevic M, Rainer F, Schwabl P, Stadlbauer V, Stauber R, Tilg H, Trauner M, Zoller H, Schöfl R, Fickert P. Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III). Wien Klin Wochenschr 2017;129:135-58. [PMID: 29063233 DOI: 10.1007/s00508-017-1262-3] [Cited by in Crossref: 62] [Cited by in F6Publishing: 49] [Article Influence: 12.4] [Reference Citation Analysis]
49 Kerbert AJ, Chiang FW, van der Werf M, Stijnen T, Slingerland H, Verspaget HW, van Hoek B, Coenraad MJ. Hemodynamic response to primary prophylactic therapy with nonselective β-blockers is related to a reduction of first variceal bleeding risk in liver cirrhosis: a meta-analysis. Eur J Gastroenterol Hepatol 2017;29:380-7. [PMID: 28002118 DOI: 10.1097/MEG.0000000000000812] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
50 Moctezuma-Velazquez C, Kalainy S, Abraldes JG. Beta-blockers in patients with advanced liver disease: Has the dust settled? Liver Transpl. 2017;23:1058-1069. [PMID: 28590564 DOI: 10.1002/lt.24794] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
51 Silva-junior G, Turon F, Baiges A, Cerda E, García-criado Á, Blasi A, Torres F, Hernandez-gea V, Bosch J, Garcia-pagan JC. Timing Affects Measurement of Portal Pressure Gradient After Placement of Transjugular Intrahepatic Portosystemic Shunts in Patients With Portal Hypertension. Gastroenterology 2017;152:1358-65. [DOI: 10.1053/j.gastro.2017.01.011] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
52 Leung JC, Loong TC, Pang J, Wei JL, Wong VW. Invasive and non-invasive assessment of portal hypertension. Hepatol Int 2018;12:44-55. [PMID: 28361299 DOI: 10.1007/s12072-017-9795-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
53 Chapman T, Dubinsky T, Barr RG. Ultrasound Elastography of the Liver: What the Clinician Needs to Know: Ultrasound Elastography of the Liver. J Ultrasound Med 2017;36:1293-304. [DOI: 10.7863/ultra.16.08001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
54 Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology 2017;65:310-35. [PMID: 27786365 DOI: 10.1002/hep.28906] [Cited by in Crossref: 918] [Cited by in F6Publishing: 722] [Article Influence: 183.6] [Reference Citation Analysis]
55 Reiberger T, Mandorfer M. Beta adrenergic blockade and decompensated cirrhosis. J Hepatol. 2017;66:849-859. [PMID: 27864004 DOI: 10.1016/j.jhep.2016.11.001] [Cited by in Crossref: 74] [Cited by in F6Publishing: 53] [Article Influence: 12.3] [Reference Citation Analysis]
56 Mandorfer M, Reiberger T. Beta blockers and cirrhosis, 2016. Dig Liver Dis. 2017;49:3-10. [PMID: 27717792 DOI: 10.1016/j.dld.2016.09.013] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 7.7] [Reference Citation Analysis]
57 Trebicka J, von Heydebrand M, Lehmann J, Tofteng F, Busk T, Jensen HL, Rohde J, Reiberger T, Mortensen C, Schierwagen R, Klein S, Møller S, Bendtsen F, Krag A. Assessment of response to beta-blockers by expression of βArr2 and RhoA/ROCK2 in antrum mucosa in cirrhotic patients. Journal of Hepatology 2016;64:1265-73. [DOI: 10.1016/j.jhep.2016.01.022] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
58 Kirnake V, Arora A, Gupta V, Sharma P, Singla V, Bansal N, Goyal M, Chawlani R, Kumar A. Hemodynamic Response to Carvedilol is Maintained for Long Periods and Leads to Better Clinical Outcome in Cirrhosis: A Prospective Study. J Clin Exp Hepatol 2016;6:175-85. [PMID: 27746613 DOI: 10.1016/j.jceh.2016.01.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
59 Villanueva C, Albillos A, Genescà J, Abraldes JG, Calleja JL, Aracil C, Bañares R, Morillas R, Poca M, Peñas B, Augustin S, Garcia-Pagan JC, Pavel O, Bosch J. Development of hyperdynamic circulation and response to β-blockers in compensated cirrhosis with portal hypertension. Hepatology 2016;63:197-206. [PMID: 26422126 DOI: 10.1002/hep.28264] [Cited by in Crossref: 103] [Cited by in F6Publishing: 81] [Article Influence: 17.2] [Reference Citation Analysis]
60 Silva-Junior G, Baiges A, Turon F, Torres F, Hernández-Gea V, Bosch J, García-Pagán JC. The prognostic value of hepatic venous pressure gradient in patients with cirrhosis is highly dependent on the accuracy of the technique. Hepatology 2015;62:1584-92. [PMID: 26238376 DOI: 10.1002/hep.28031] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 5.7] [Reference Citation Analysis]
61 Tripathi D, Stanley AJ, Hayes PC, Patch D, Millson C, Mehrzad H, Austin A, Ferguson JW, Olliff SP, Hudson M, Christie JM; Clinical Services and Standards Committee of the British Society of Gastroenterology. U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut 2015;64:1680-704. [PMID: 25887380 DOI: 10.1136/gutjnl-2015-309262] [Cited by in Crossref: 306] [Cited by in F6Publishing: 253] [Article Influence: 43.7] [Reference Citation Analysis]
62 Mohanty A, Tate JP, Garcia-Tsao G. Statins Are Associated With a Decreased Risk of Decompensation and Death in Veterans With Hepatitis C-Related Compensated Cirrhosis. Gastroenterology. 2016;150:430-40.e1. [PMID: 26484707 DOI: 10.1053/j.gastro.2015.10.007] [Cited by in Crossref: 100] [Cited by in F6Publishing: 86] [Article Influence: 14.3] [Reference Citation Analysis]
63 Garcia-Tsao G, Bosch J. Varices and Variceal Hemorrhage in Cirrhosis: A New View of an Old Problem. Clin Gastroenterol Hepatol. 2015;13:2109-2117. [PMID: 26192141 DOI: 10.1016/j.cgh.2015.07.012] [Cited by in Crossref: 46] [Cited by in F6Publishing: 34] [Article Influence: 6.6] [Reference Citation Analysis]
64 Sauerbruch T, Mengel M, Dollinger M, Zipprich A, Rössle M, Panther E, Wiest R, Caca K, Hoffmeister A, Lutz H, Schoo R, Lorenzen H, Trebicka J, Appenrodt B, Schepke M, Fimmers R; German Study Group for Prophylaxis of Variceal Rebleeding. Prevention of Rebleeding From Esophageal Varices in Patients With Cirrhosis Receiving Small-Diameter Stents Versus Hemodynamically Controlled Medical Therapy. Gastroenterology 2015;149:660-8.e1. [PMID: 25989386 DOI: 10.1053/j.gastro.2015.05.011] [Cited by in Crossref: 123] [Cited by in F6Publishing: 92] [Article Influence: 17.6] [Reference Citation Analysis]
65 Yan K, Bridges JF, Augustin S, Laine L, Garcia-Tsao G, Fraenkel L. Factors impacting physicians' decisions to prevent variceal hemorrhage. BMC Gastroenterol 2015;15:55. [PMID: 25934271 DOI: 10.1186/s12876-015-0287-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
66 Bhutta AQ, Garcia-Tsao G. The Role of Medical Therapy for Variceal Bleeding. Gastrointest Endosc Clin N Am 2015;25:479-90. [PMID: 26142033 DOI: 10.1016/j.giec.2015.03.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
67 Mura VL, Nicolini A, Tosetti G, Primignani M. Cirrhosis and portal hypertension: The importance of risk stratification, the role of hepatic venous pressure gradient measurement. World J Hepatol 2015; 7(4): 688-695 [PMID: 25866605 DOI: 10.4254/wjh.v7.i4.688] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 6.0] [Reference Citation Analysis]
68 Suk KT, Kim DJ. Staging of liver fibrosis or cirrhosis: The role of hepatic venous pressure gradient measurement. World J Hepatol 2015; 7(3): 607-615 [PMID: 25848485 DOI: 10.4254/wjh.v7.i3.607] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 5.7] [Reference Citation Analysis]
69 Neill S, Engoren M, Kouatli Y, Shields TA, Jewell E, Pagani FD. Risk factors related to transfusion requirements in patients undergoing implantation of ventricular assist devices. J Cardiothorac Vasc Anesth 2015;29:297-302. [PMID: 25488077 DOI: 10.1053/j.jvca.2014.07.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
70 Ilyas JA, Kanwal F. Primary prophylaxis of variceal bleeding. Gastroenterol Clin North Am 2014;43:783-94. [PMID: 25440925 DOI: 10.1016/j.gtc.2014.08.008] [Cited by in Crossref: 4] [Article Influence: 0.5] [Reference Citation Analysis]
71 Du QH, Han L, Jiang JJ, Xu Y, Li WH, Li PT, Wang XY, Jia X. Glytan decreases portal pressure via mesentery vasoconstriction in portal hypertensive rats. World J Gastroenterol 2014; 20(44): 16674-16682 [PMID: 25469036 DOI: 10.3748/wjg.v20.i44.16674] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
72 Kreisel W, Deibert P, Kupcinskas L, Sumskiene J, Appenrodt B, Roth S, Neagu M, Rössle M, Zipprich A, Caca K, Ferlitsch A, Dilger K, Mohrbacher R, Greinwald R, Sauerbruch T. The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study. Dig Liver Dis 2015;47:144-50. [PMID: 25483910 DOI: 10.1016/j.dld.2014.10.018] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
73 Triantos C, Kalafateli M. Endoscopic treatment of esophageal varices in patients with liver cirrhosis. World J Gastroenterol 2014;20:13015-26. [PMID: 25278695 DOI: 10.3748/wjg.v20.i36.13015] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
74 Abraldes JG, Sarlieve P, Tandon P. Measurement of portal pressure. Clin Liver Dis. 2014;18:779-792. [PMID: 25438283 DOI: 10.1016/j.cld.2014.07.002] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 4.6] [Reference Citation Analysis]
75 Triantos C, Kalafateli M. Primary prevention of bleeding from esophageal varices in patients with liver cirrhosis. World J Hepatol 2014;6:363-9. [PMID: 25018847 DOI: 10.4254/wjh.v6.i6.363] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
76 Karadsheh Z, Allison H. Primary prevention of variceal bleeding: pharmacological therapy versus endoscopic banding. N Am J Med Sci. 2013;5:573-579. [PMID: 24350068 DOI: 10.4103/1947-2714.120791] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
77 Patwardhan VR, Cardenas A. Review article: the management of portal hypertensive gastropathy and gastric antral vascular ectasia in cirrhosis. Aliment Pharmacol Ther. 2014;40:354-362. [PMID: 24889902 DOI: 10.1111/apt.12824] [Cited by in Crossref: 49] [Cited by in F6Publishing: 35] [Article Influence: 6.1] [Reference Citation Analysis]
78 Gomez EV, Gonzalez AT, Bertot LC, Yasells Garcia A, Rodriguez YS, Perez YM. Arterial blood pressure is closely related to ascites development in compensated HCV-related cirrhosis. PLoS One 2014;9:e95736. [PMID: 24755710 DOI: 10.1371/journal.pone.0095736] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
79 Kim MY, Jeong WK, Baik SK. Invasive and non-invasive diagnosis of cirrhosis and portal hypertension. World J Gastroenterol 2014; 20(15): 4300-4315 [PMID: 24764667 DOI: 10.3748/wjg.v20.i15.4300] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 59] [Article Influence: 8.6] [Reference Citation Analysis]
80 Bai M, Qi X, Yang M, Han G, Fan D. Combined therapies versus monotherapies for the first variceal bleeding in patients with high-risk varices: A meta-analysis of randomized controlled trials: Primary prevention of variceal bleeding. J Gastroenterol Hepatol 2014;29:442-52. [DOI: 10.1111/jgh.12396] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
81 Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014;383:1749-1761. [PMID: 24480518 DOI: 10.1016/s0140-6736(14)60121-5] [Cited by in Crossref: 801] [Cited by in F6Publishing: 395] [Article Influence: 100.1] [Reference Citation Analysis]
82 Shah HA, Azam Z, Rauf J, Abid S, Hamid S, Jafri W, Khalid A, Ismail FW, Parkash O, Subhan A, Munir SM. Carvedilol vs. esophageal variceal band ligation in the primary prophylaxis of variceal hemorrhage: a multicentre randomized controlled trial. J Hepatol. 2014;60:757-764. [PMID: 24291366 DOI: 10.1016/j.jhep.2013.11.019] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 5.4] [Reference Citation Analysis]
83 Tripathi D, Hayes PC. Beta-blockers in portal hypertension: new developments and controversies. Liver Int. 2014;34:655-667. [PMID: 24134058 DOI: 10.1111/liv.12360] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
84 Reverter E, Blasi A, Abraldes JG, Martínez-Palli G, Seijo S, Turon F, Berzigotti A, Balust J, Bosch J, García-Pagán JC. Impact of deep sedation on the accuracy of hepatic and portal venous pressure measurements in patients with cirrhosis. Liver Int 2014;34:16-25. [PMID: 23763484 DOI: 10.1111/liv.12229] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
85 Berzigotti A, Seijo S, Reverter E, Bosch J. Assessing portal hypertension in liver diseases. Expert Rev Gastroenterol Hepatol. 2013;7:141-155. [PMID: 23363263 DOI: 10.1586/egh.12.83] [Cited by in Crossref: 144] [Cited by in F6Publishing: 107] [Article Influence: 16.0] [Reference Citation Analysis]
86 O'Brien J, Triantos C, Burroughs AK. Management of varices in patients with cirrhosis. Nat Rev Gastroenterol Hepatol 2013;10:402-12. [PMID: 23545523 DOI: 10.1038/nrgastro.2013.51] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
87 Schepis F, Vukotic R, Berzigotti A, Carrión JA, Forns X, Abraldes JG, García-valdecasas J, Navasa M, García-pagán J, Bosch J. Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: A case-control study: Response to Propranolol in Liver Transplantation. Liver Transpl 2013;19:450-6. [DOI: 10.1002/lt.23614] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
88 Vorobioff JD, Groszmann RJ. Hepatic venous pressure gradient measurement in pre-primary and primary prophylaxis of variceal hemorrhage. Annals of Hepatology 2013;12:22-9. [DOI: 10.1016/s1665-2681(19)31381-x] [Cited by in Crossref: 12] [Article Influence: 1.3] [Reference Citation Analysis]
89 Bureau C, Di Martino V, Calès P. A major new step in non-invasive evaluation of portal hypertension: elastography. Liver Int. 2013;33:4-6. [PMID: 23121438 DOI: 10.1111/liv.12008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
90 Hobolth L, Bendtsen F, Møller S. Indications for portal pressure measurement in chronic liver disease. Scandinavian Journal of Gastroenterology 2012;47:887-92. [DOI: 10.3109/00365521.2012.706827] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
91 Addley J, Tham TC, Cash WJ. Use of portal pressure studies in the management of variceal haemorrhage. World J Gastrointest Endosc 2012; 4(7): 281-289 [PMID: 22816007 DOI: 10.4253/wjge.v4.i7.281] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
92 Al-Busafi SA, Ghali P, Wong P, Deschenes M. Endoscopic management of portal hypertension. Int J Hepatol 2012;2012:747095. [PMID: 22830037 DOI: 10.1155/2012/747095] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
93 Bosch J, Abraldes JG, Albillos A, Aracil C, Bañares R, Berzigotti A, Calleja JL, de la Peña J, Escorsell A, García-pagán JC, Genescà J, Hernández-guerra M, Ripoll C, Planas R, Villanueva C. Hipertensión portal: recomendaciones para su evaluación y tratamiento. Gastroenterología y Hepatología 2012;35:421-50. [DOI: 10.1016/j.gastrohep.2012.02.009] [Cited by in Crossref: 27] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
94 Ripoll C, Lastra P, Rincón D, Catalina V, Bañares R. Comparison of MELD, HVPG, and their changes to predict clinically relevant endpoints in cirrhosis. Scand J Gastroenterol 2012;47:204-11. [PMID: 22242615 DOI: 10.3109/00365521.2011.645500] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
95 Abraldes JG, Araujo IK, Turón F, Berzigotti A. Diagnosing and monitoring cirrhosis: Liver biopsy, hepatic venous pressure gradient and elastography. Gastroenterol Hepatol. 2012;35:488-495. [PMID: 22560536 DOI: 10.1016/j.gastrohep.2012.02.010] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
96 Erice E, Llop E, Berzigotti A, Abraldes JG, Conget I, Seijo S, Reverter E, Albillos A, Bosch J, García-Pagán JC. Insulin resistance in patients with cirrhosis and portal hypertension. Am J Physiol Gastrointest Liver Physiol. 2012;302:G1458-G1465. [PMID: 22492691 DOI: 10.1152/ajpgi.00389.2011] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
97 Bari K, Garcia-Tsao G. Treatment of portal hypertension. World J Gastroenterol 2012; 18(11): 1166-1175 [PMID: 22468079 DOI: 10.3748/wjg.v18.i11.1166] [Cited by in CrossRef: 88] [Cited by in F6Publishing: 82] [Article Influence: 8.8] [Reference Citation Analysis]
98 Sarin SK, Mishra SR, Sharma P, Sharma BC, Kumar A. Early primary prophylaxis with beta-blockers does not prevent the growth of small esophageal varices in cirrhosis: a randomized controlled trial. Hepatol Int 2013;7:248-56. [PMID: 26201639 DOI: 10.1007/s12072-012-9353-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
99 Hobolth L, Møller S, Grønbæk H, Roelsgaard K, Bendtsen F, Feldager Hansen E. Carvedilol or propranolol in portal hypertension? A randomized comparison. Scandinavian Journal of Gastroenterology 2012;47:467-74. [DOI: 10.3109/00365521.2012.666673] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
100 Hernández-gea V, Aracil C, Colomo A, Garupera I, Poca M, Torras X, Miñana J, Guarner C, Villanueva C. Development of Ascites in Compensated Cirrhosis With Severe Portal Hypertension Treated With β-Blockers. American Journal of Gastroenterology 2012;107:418-27. [DOI: 10.1038/ajg.2011.456] [Cited by in Crossref: 87] [Cited by in F6Publishing: 65] [Article Influence: 8.7] [Reference Citation Analysis]
101 González A, Augustin S, Dot J, Pérez M, Abu-Suboh M, Romero A, Segarra A, Armengol JR, Esteban R, Guardia J. Adding banding ligation is effective as rescue therapy to prevent variceal rebleeding in haemodynamic non-responders to pharmacological therapy. Dig Liver Dis. 2012;44:55-60. [PMID: 21890439 DOI: 10.1016/j.dld.2011.07.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
102 Tripathi D. Primary prophylaxis against gastric variceal bleeding: is there a sticky solution at last? Hepatology 2011;54:1094-6. [PMID: 22179988 DOI: 10.1002/hep.24499] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
103 Opio CK, Garcia-tsao G. Managing Varices: Drugs, Bands, and Shunts. Gastroenterology Clinics of North America 2011;40:561-79. [DOI: 10.1016/j.gtc.2011.06.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
104 Castera L, Pinzani M, Bosch J. Non invasive evaluation of portal hypertension using transient elastography. J Hepatol. 2012;56:696-703. [PMID: 21767510 DOI: 10.1016/j.jhep.2011.07.005] [Cited by in Crossref: 215] [Cited by in F6Publishing: 175] [Article Influence: 19.5] [Reference Citation Analysis]
105 Merkel C, Montagnese S. Hepatic venous pressure gradient measurement in clinical hepatology. Dig Liver Dis 2011;43:762-7. [PMID: 21549649 DOI: 10.1016/j.dld.2011.03.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
106 Miñano C, Garcia-Tsao G. Clinical pharmacology of portal hypertension. Gastroenterol Clin North Am 2010;39:681-95. [PMID: 20951924 DOI: 10.1016/j.gtc.2010.08.015] [Cited by in Crossref: 44] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
107 Ripoll C, Garcia-Tsao G. The management of portal hypertensive gastropathy and gastric antral vascular ectasia. Dig Liver Dis. 2011;43:345-351. [PMID: 21095166 DOI: 10.1016/j.dld.2010.10.006] [Cited by in Crossref: 52] [Cited by in F6Publishing: 40] [Article Influence: 4.3] [Reference Citation Analysis]
108 Tsochatzis EA, Triantos CK, Garcovich M, Burroughs AK. Primary prevention of variceal hemorrhage. Curr Gastroenterol Rep 2011;13:3-9. [PMID: 21086193 DOI: 10.1007/s11894-010-0160-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
109 Al-Hamoudi WK. Cardiovascular changes in cirrhosis: pathogenesis and clinical implications. Saudi J Gastroenterol. 2010;16:145-153. [PMID: 20616408 DOI: 10.4103/1319-3767.65181] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
110 Zipprich A, Winkler M, Seufferlein T, Dollinger MM. Comparison of balloon vs. straight catheter for the measurement of portal hypertension. Aliment Pharmacol Ther. 2010;32:1351-1356. [PMID: 21050237 DOI: 10.1111/j.1365-2036.2010.04484.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
111 Merkel C, Montagnese S. Should we routinely measure portal pressure in patients with cirrhosis, using hepatic venous pressure gradient (HVPG) as guidance for prophylaxis and treatment of bleeding and re-bleeding? Yes! Eur J Intern Med 2011;22:1-4. [PMID: 21238883 DOI: 10.1016/j.ejim.2010.08.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
112 Solà E, Ginès P. Renal and circulatory dysfunction in cirrhosis: current management and future perspectives. J Hepatol 2010;53:1135-45. [PMID: 20850887 DOI: 10.1016/j.jhep.2010.08.001] [Cited by in Crossref: 71] [Cited by in F6Publishing: 55] [Article Influence: 5.9] [Reference Citation Analysis]
113 Lo GH, Chen WC, Wang HM, Lee CC. Controlled trial of ligation plus nadolol versus nadolol alone for the prevention of first variceal bleeding. Hepatology 2010;52:230-7. [PMID: 20578138 DOI: 10.1002/hep.23617] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
114 Miraglia R, Luca A, Maruzzelli L, Spada M, Riva S, Caruso S, Maggiore G, Gridelli B, Bosch J. Measurement of hepatic vein pressure gradient in children with chronic liver diseases. J Hepatol. 2010;53:624-629. [PMID: 20615572 DOI: 10.1016/j.jhep.2010.04.027] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
115 Bosch J. Carvedilol for portal hypertension in patients with cirrhosis. Hepatology 2010;51:2214-8. [PMID: 20513005 DOI: 10.1002/hep.23689] [Cited by in Crossref: 57] [Cited by in F6Publishing: 48] [Article Influence: 4.8] [Reference Citation Analysis]
116 Burroughs AK, Thalheimer U. Hepatic venous pressure gradient in 2010: optimal measurement is key. Hepatology 2010;51:1894-6. [PMID: 20512984 DOI: 10.1002/hep.23710] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 3.0] [Reference Citation Analysis]
117 Albillos A, Peñas B, Zamora J. Role of Endoscopy in Primary Prophylaxis for Esophageal Variceal Bleeding. Clinics in Liver Disease 2010;14:231-50. [DOI: 10.1016/j.cld.2010.03.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
118 Guarner-Argente C, Sánchez E, Vidal S, Román E, Concepción M, Poca M, Sánchez D, Juárez C, Soriano G, Guarner C. Toll-like receptor 4 D299G polymorphism and the incidence of infections in cirrhotic patients. Aliment Pharmacol Ther. 2010;31:1192-1199. [PMID: 20222908 DOI: 10.1111/j.1365-2036.2010.04291.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
119 Bosch J, Abraldes JG, Berzigotti A, García-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol 2009;6:573-82. [PMID: 19724251 DOI: 10.1038/nrgastro.2009.149] [Cited by in Crossref: 425] [Cited by in F6Publishing: 363] [Article Influence: 32.7] [Reference Citation Analysis]